Showing 651-660 of 1791 results for "".
Creating An Enjoyable Experience
https://practicaldermatology.com/topics/practice-management/creating-an-enjoyable-experience/20732/How to establish a healthy practice culture that satisfies staff.Biosimilars: Generic Biologics or Something Much More Complex?
https://practicaldermatology.com/topics/practice-management/biosimilars-generic-biologics-or-something-much-more-complex/21013/The looming availability of biosimilar medications raises important clinical and regulatory questions.Kybella Off-Label?
https://practicaldermatology.com/topics/practice-management/kybellaoff-label/21057/Experts weigh in on whether and how Kybella® may be used off-label.EGFR Inhibitor-induced Acneiform Rash: A Review of Current Management Strategies
https://practicaldermatology.com/topics/general-topics/egfr-inhibitor-induced-acneiform-rash-a-review-of-current-management-strategies/21517/Update on Sunscreen Labeling and Regulation
https://practicaldermatology.com/topics/general-topics/update-on-sunscreen-labeling-and-regulation/21640/Simpler, clearer labeling and packaging may likely lead to better understandings of how proper sunscreen use can help prevent skin cancer.An Update on At-Home UVB Phototherapy
https://practicaldermatology.com/topics/general-topics/an-update-on-at-home-uvb-phototherapy/21786/At-home options increase accessibility to phototherapy, which is effective and generally safe for psoriasis management.Clinical Focus: Acne: Back in the Spotlight: Effective Options for Truncal Acne
https://practicaldermatology.com/topics/general-topics/back-in-the-spotlight-effective-options-for-truncal-acne/22031/Data suggest that patients may be unlikely to report truncal acne. Clinicians must assess chest and back involvement and be prepared to offer effective treatments.Understanding PML and Risks Associated with Biologic Therapies
https://practicaldermatology.com/topics/psoriasis/PD0509_10-php/22832/A swarm of controversy has enveloped biologics due to concerns about progressive multifocal leukoencephalopathy.Experts React to Latest Benzene Analysis
https://practicaldermatology.com/series/dermwire-tv/experts-react-to-latest-benzene-analysis/29810/In this week's DermwireTV, Practical Dermatology Editorial Board members provide their thoughts on the recent analysis examining benzene concentrations in BPO products; Johnson & Johnson seeks new indications for IL-23 inhibitor Tremfya; and the founder and CEO of Terns discusses plans to improvBeyond the Flare: Choosing the Right Systemic in Moderate-to-Severe Atopic Dermatitis
https://practicaldermatology.com/series/dermatology-hub-neuroimmune-network/beyond-the-flare-choosing-the-right-systemic-in-moderate-to-severe-atopic-dermatitis/39728/